

February 25, 2020

# Relmada Therapeutics to Present at 9th Annual SVB Leerink Global Healthcare Conference

**Company Presentation on Thursday, February 27, 2020 at 11:00 AM Eastern Time**

NEW YORK, Feb. 25, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Sergio Traversa, Chief Executive Officer of Relmada, will present a corporate overview at the 9<sup>th</sup> Annual SVB Leerink Global Healthcare Conference, taking place February 26-27, 2020, in New York City.



Details of Relmada's presentation are as follows:

**Presentation Details:**

Date: Thursday, February 27, 2020  
Time: 11:00 AM Eastern Time  
Webcast: <http://wsw.com/webcast/svbleerink34/rlmd/>

Please register at least 10 minutes prior to the start of the presentation to ensure timely access. The webcast and presentation will also be archived on the website for 90 days after the conference.

## **About Relmada Therapeutics, Inc.**

Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines to address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, dextromethadone (REL-1017), is an N-methyl-D-aspartate (NMDA) receptor antagonist in development for the treatment of depression. NMDA receptor antagonists may have utility in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.

## **Forward-Looking Statements**

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the

Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the expected use of the proceeds from the offering. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to" and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all of the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be considered to be a complete list.

Investor Contact:

Brian Ritchie  
LifeSci Advisors  
212-915-2578  
[BRitchie@LifeSciAdvisors.com](mailto:BRitchie@LifeSciAdvisors.com)

View original content to download multimedia <http://www.prnewswire.com/news-releases/relmada-therapeutics-to-present-at-9th-annual-svb-leerink-global-healthcare-conference-301010802.html>

SOURCE Relmada Therapeutics, Inc.